fingolimod hydrochloride has been researched along with Sclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endres, T; Gottmann, K; Kartalou, GI; Leßmann, V; Pawlitzki, M | 1 |
| Hirt, SW; Lehle, K; Puehler, T; Schmid, C; von Suesskind-Schwendi, M | 1 |
1 review(s) available for fingolimod hydrochloride and Sclerosis
| Article | Year |
|---|---|
Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Topics: Aged; Alzheimer Disease; Animals; Drug Repositioning; Fingolimod Hydrochloride; Humans; Inflammation; Mice; Multiple Sclerosis; Sclerosis | 2023 |
1 other study(ies) available for fingolimod hydrochloride and Sclerosis
| Article | Year |
|---|---|
Early administration of FTY720 prevents chronic airway as well as vascular destruction in experimental rat lung transplantation.
Topics: Acute Disease; Animals; Bronchiolitis Obliterans; Chronic Disease; Drug Administration Schedule; Fingolimod Hydrochloride; Graft Rejection; Immunosuppressive Agents; Lung; Lung Transplantation; Lymphocytes; Male; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Inbred WKY; Sclerosis; Sphingosine; Time Factors; Vascular Diseases | 2013 |